Find Clinical Trial

Study assessing the glucose-lowering efficacy and safety of luseogliflozin on top of metformin in Caucasian patients with type 2 diabetes mellitus


← Back
Study Phase

Phase 3

Therapeutic Area

Metabolism

IndicationDiabetes - Type II
SponsorJSC Servier (Russia)
Active substance/
Medical device

Luseogliflozin

Active Substance CodeLuseogliflozin
Protocol CodeCL3-LUSEO-001
ISRCTN CodeISRCTN39549850


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility